Home Cart 0 Sign in  
X

[ CAS No. 870-46-2 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
3d Animation Molecule Structure of 870-46-2
Chemical Structure| 870-46-2
Chemical Structure| 870-46-2
Structure of 870-46-2 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 870-46-2 ]

Related Doc. of [ 870-46-2 ]

Alternatived Products of [ 870-46-2 ]

Product Details of [ 870-46-2 ]

CAS No. :870-46-2 MDL No. :MFCD00007593
Formula : C5H12N2O2 Boiling Point : -
Linear Structure Formula :- InChI Key :DKACXUFSLUYRFU-UHFFFAOYSA-N
M.W : 132.16 Pubchem ID :70091
Synonyms :

Calculated chemistry of [ 870-46-2 ]

Physicochemical Properties

Num. heavy atoms : 9
Num. arom. heavy atoms : 0
Fraction Csp3 : 0.8
Num. rotatable bonds : 3
Num. H-bond acceptors : 3.0
Num. H-bond donors : 2.0
Molar Refractivity : 33.37
TPSA : 64.35 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.98 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.58
Log Po/w (XLOGP3) : 0.18
Log Po/w (WLOGP) : 0.38
Log Po/w (MLOGP) : 0.38
Log Po/w (SILICOS-IT) : -1.03
Consensus Log Po/w : 0.3

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -0.57
Solubility : 35.2 mg/ml ; 0.266 mol/l
Class : Very soluble
Log S (Ali) : -1.09
Solubility : 10.8 mg/ml ; 0.0814 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -0.44
Solubility : 48.3 mg/ml ; 0.366 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 2.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.76

Safety of [ 870-46-2 ]

Signal Word:Danger Class:4.1
Precautionary Statements:P210-P240-P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P370+P378-P403+P233-P501 UN#:1325
Hazard Statements:H228-H302-H315-H319-H335 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 870-46-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 870-46-2 ]
  • Downstream synthetic route of [ 870-46-2 ]

[ 870-46-2 ] Synthesis Path-Upstream   1~50

  • 1
  • [ 870-46-2 ]
  • [ 670-54-2 ]
  • [ 54385-49-8 ]
Reference: [1] Patent: JP5654467, 2015, B2, . Location in patent: Paragraph 0082-0084
[2] Patent: WO2018/89786, 2018, A1, . Location in patent: Paragraph 00177
  • 2
  • [ 20866-46-0 ]
  • [ 870-46-2 ]
  • [ 17791-52-5 ]
Reference: [1] Chemistry of Natural Compounds, 1982, vol. 18, # 3, p. 322 - 327[2] Khimiya Prirodnykh Soedinenii, 1982, # 3, p. 349 - 354
  • 3
  • [ 870-46-2 ]
  • [ 36016-38-3 ]
Reference: [1] Journal of the American Chemical Society, 1959, vol. 81, p. 955
  • 4
  • [ 24424-99-5 ]
  • [ 870-46-2 ]
YieldReaction ConditionsOperation in experiment
97% With hydrazine hydrate In isopropyl alcohol at 0℃; for 2 h; Hydrazine hydrate (113 mg, 2.26 mmol, 2.26 equiv) was dissolved in IPA (5 mL) and cooled down to 0 °C. Di-tert-butyl carbonate (174 mg, 1 mmol, 1 equiv) in IPA (1 mL) was added drop-wise and the mixture was stirred for 2 h. The solvent was then evaporated and the residue was dissolved in DCM, dried over MgSO4, and filtered. Evaporation of the solvent gave tert-butyl hydrazinecarboxylate 10 as a white semi-solid (128 mg, 97percent). 1H NMR (300 MHz, CDCl3) δ 6.73(s, 1H), 3.83 (s, 2H), 1.46 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 158.2, 80.1, 28.2.21
93% With potassium carbonate; hydrazine hydrate In 1,4-dioxane; water at 20℃; for 12 h; A solution of di-tert-butyl dicarbonate (2.91 g, 13.3 mmol) in dioxane(50 mL) was dropwise added to a solution of K2CO3 (7.35 g,53.2 mmol) and hydrazine hydrate (2.58 mL, 53.2 mmol) in water(50 mL), and the mixture was stirred at r.t. for 12 h. Two phaseswere formed, separated, and then the aqueous phase was washedwith ethyl ether (2 × 25 mL). The ether phase was added to the dioxanephase, and the total organic solution was evaporated. The colorlessoil obtained was distilled under vacuum, and the pure productwas obtained as the sublimated white crystals (1.64 g, 93percent yield),m.p. 38–39 °C. 1H NMR (CDCl3) δ (ppm): 5.83 (bs, 1H, NHBoc), 3.67(d, J = 3.0 Hz, 2H, NH2), 1.45 (s, 9H, t-BuH); m/z (ESI MS): 155.0(M + Na)+.
90% With hydrazine hydrate; toluene-4-sulfonic acid In water at -5 - 0℃; for 1.5 h; Add 500ml of water and 50g of hydrazine hydrate (0.8mol) with a mass concentration of 80percent to a 5L reaction flask, and start stirring.Controlled temperature -5 ~ 0 °C batchwise addition of monohydrate p-toluene sulfonic acid 152g (0.8mol), plus complete the next -5 ~ 0 °C reaction 0.5 hours, then addBOC anhydride (di-tert-butyl dicarbonate) 174 g (0.8 mol), stir at -5 to 0°C for 1 hour, add 400 ml of dichloromethane,Liquid caustic soda was added dropwise to pH=11-12, and the organic phase was concentrated to dryness under reduced pressure. 200 g of petroleum ether was added and stirred for 0.5 hours.After suction filtration, the solid product was dried and used as the target product BOC-; the resulting solid had a weight of 95 g, a purity of 99.9percent, and a yield of 90percent.
80% With hydrazine hydrate In isopropyl alcohol at 0 - 10℃; for 0.5 h; Cooling with ice With the stirrer in three-opening reaction bottle 30 g of hydrazine hydrate and the isopropanol added 150 ml, ice water bath cooling by the addition of BOC anhydride 111.6 g isopropanol solution of 120 ml, 0 - 10 °C degrees stirring 0.5h to the reaction is complete, concentrated to solution is clarified, dichloromethane 100 ml by adding, dried with anhydrous sodium sulfate, concentrated under reduced pressure to obtain white solid. The resulting crude product using petroleum ether 200 ml of beating, the decompression to obtain white solid 35.7 g, LC purity 55percent or more, the yield is 80percent.
70% With hydrazine hydrate In tetrahydrofuran at 0℃; for 1 h; To a round bottom flask equipped with a stir bar, 25 mmol of hydrazine monohydrate was dissolved in THF at 0 °C. Added drop-wise to this was a solution of Boc2O in THF. The reaction was allowed to mix at 0 °C for an additional hour. The reaction was then diluted with ethyl acetate and washed with water (2.x.). The organic layer was dried over Na2SO4 and the solvent was removed under reduced pressure. 3.53 mmol of desired product was collected (70percent yield). LCMS: tR = 7.23 min. m/z = 133.2 (M+H).

Reference: [1] European Journal of Medicinal Chemistry, 2012, vol. 54, p. 33 - 41
[2] Tetrahedron Letters, 2015, vol. 56, # 48, p. 6653 - 6655
[3] Journal of Inorganic Biochemistry, 2013, vol. 127, p. 188 - 202
[4] Organic and Biomolecular Chemistry, 2017, vol. 15, # 43, p. 9071 - 9076
[5] Journal of Materials Chemistry B, 2017, vol. 5, # 19, p. 3565 - 3571
[6] Patent: CN108003062, 2018, A, . Location in patent: Paragraph 0022; 0023
[7] Organic and Biomolecular Chemistry, 2016, vol. 14, # 5, p. 1579 - 1583
[8] Patent: CN106565531, 2017, A, . Location in patent: Paragraph 0036; 0039-0042
[9] Journal of the American Chemical Society, 2004, vol. 126, # 21, p. 6759 - 6764
[10] Chemistry - An Asian Journal, 2018, vol. 13, # 19, p. 2854 - 2867
[11] Tetrahedron, 2008, vol. 64, # 28, p. 6788 - 6793
[12] Chemical Communications, 2012, vol. 48, # 65, p. 8129 - 8131
[13] Bioorganic and Medicinal Chemistry, 2012, vol. 20, # 1, p. 487 - 497
[14] Journal of Medicinal Chemistry, 2018, vol. 61, # 18, p. 8255 - 8281
[15] Journal of Organic Chemistry USSR (English Translation), 1977, vol. 13, # 12, p. 2352 - 2355[16] Zhurnal Organicheskoi Khimii, 1977, vol. 13, # 12, p. 2531 - 2535
[17] Chemistry of Natural Compounds, 1982, vol. 18, # 3, p. 322 - 327[18] Khimiya Prirodnykh Soedinenii, 1982, # 3, p. 349 - 354
[19] Molecular Pharmaceutics, 2010, vol. 7, # 4, p. 953 - 962
[20] Patent: WO2015/139263, 2015, A1, . Location in patent: Page/Page column 6; 7
[21] Green Chemistry, 2018, vol. 20, # 21, p. 4859 - 4864
  • 5
  • [ 51300-90-4 ]
  • [ 870-46-2 ]
Reference: [1] European Journal of Medicinal Chemistry, 2015, vol. 96, p. 330 - 339
  • 6
  • [ 6627-89-0 ]
  • [ 870-46-2 ]
Reference: [1] Tetrahedron Letters, 1991, vol. 32, # 26, p. 3079 - 3082
[2] Journal of the American Chemical Society, 1957, vol. 79, p. 98,100
[3] Org. Synth. Coll. Vol. V <1973> 168,
  • 7
  • [ 1860-21-5 ]
  • [ 870-46-2 ]
Reference: [1] Journal of the American Chemical Society, 1960, vol. 82, p. 2725 - 2727
  • 8
  • [ 29518-83-0 ]
  • [ 870-46-2 ]
Reference: [1] Org. Synth. Coll. Vol. V <1973> 166,
[2] Journal of the American Chemical Society, 1960, vol. 82, p. 2725 - 2727
  • 9
  • [ 99969-78-5 ]
  • [ 870-46-2 ]
Reference: [1] Journal of the American Chemical Society, 1960, vol. 82, p. 2725 - 2727
  • 10
  • [ 1694-31-1 ]
  • [ 870-46-2 ]
Reference: [1] Patent: WO2013/67646, 2013, A1, . Location in patent: Page/Page column 00370
  • 11
  • [ 57022-34-1 ]
  • [ 870-46-2 ]
Reference: [1] Bulletin de l'Academie Polonaise des Sciences, Serie des Sciences Chimiques, 1964, vol. 12, p. 21 - 24
  • 12
  • [ 60470-15-7 ]
  • [ 870-46-2 ]
Reference: [1] Journal of Organic Chemistry USSR (English Translation), 1976, vol. 12, # 7, p. 1396 - 1399[2] Zhurnal Organicheskoi Khimii, 1976, vol. 12, # 7, p. 1407 - 1410
  • 13
  • [ 68058-85-5 ]
  • [ 870-46-2 ]
Reference: [1] Journal of Organic Chemistry USSR (English Translation), 1978, vol. 14, p. 1500 - 1507[2] Zhurnal Organicheskoi Khimii, 1978, vol. 14, p. 1605 - 1613
  • 14
  • [ 4248-19-5 ]
  • [ 870-46-2 ]
Reference: [1] Journal of Organic Chemistry USSR (English Translation), 1978, vol. 14, p. 1500 - 1507[2] Zhurnal Organicheskoi Khimii, 1978, vol. 14, p. 1605 - 1613
  • 15
  • [ 20866-46-0 ]
  • [ 870-46-2 ]
  • [ 17791-52-5 ]
Reference: [1] Chemistry of Natural Compounds, 1982, vol. 18, # 3, p. 322 - 327[2] Khimiya Prirodnykh Soedinenii, 1982, # 3, p. 349 - 354
  • 16
  • [ 24424-99-5 ]
  • [ 302-01-2 ]
  • [ 870-46-2 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 18, p. 5070 - 5076
  • 17
  • [ 75-44-5 ]
  • [ 75-65-0 ]
  • [ 870-46-2 ]
Reference: [1] Bulletin of the Chemical Society of Japan, 1969, vol. 42, p. 809 - 811
  • 18
  • [ 870-46-2 ]
  • [ 85006-25-3 ]
Reference: [1] Journal of the American Chemical Society, 1959, vol. 81, p. 955
[2] Journal of the American Chemical Society, 1959, vol. 81, p. 955
  • 19
  • [ 870-46-2 ]
  • [ 16466-61-8 ]
Reference: [1] Organic Letters, 2003, vol. 5, # 22, p. 4129 - 4131
  • 20
  • [ 870-46-2 ]
  • [ 16466-61-8 ]
Reference: [1] Patent: US5494889, 1996, A,
  • 21
  • [ 1070-19-5 ]
  • [ 870-46-2 ]
  • [ 16466-61-8 ]
Reference: [1] Journal of the American Chemical Society, 1957, vol. 79, p. 4427,4429
  • 22
  • [ 870-46-2 ]
  • [ 57022-34-1 ]
  • [ 16466-61-8 ]
Reference: [1] Journal of the American Chemical Society, 1960, vol. 82, p. 2725 - 2727
  • 23
  • [ 870-46-2 ]
  • [ 24424-99-5 ]
  • [ 16466-61-8 ]
Reference: [1] Tetrahedron, 2008, vol. 64, # 28, p. 6788 - 6793
  • 24
  • [ 870-46-2 ]
  • [ 67-64-1 ]
  • [ 16689-35-3 ]
Reference: [1] Dalton Transactions, 2018, vol. 47, # 14, p. 4785 - 4789
[2] Journal of Medicinal Chemistry, 2007, vol. 50, # 20, p. 4789 - 4792
  • 25
  • [ 870-46-2 ]
  • [ 16689-35-3 ]
Reference: [1] Journal of the American Chemical Society, 2004, vol. 126, # 21, p. 6759 - 6764
[2] Polish Journal of Chemistry, 2002, vol. 76, # 12, p. 1693 - 1697
[3] Journal of the Chemical Society. Perkin transactions 1, 1975, # 17, p. 1712 - 1720
[4] Journal of the American Chemical Society, 1963, vol. 85, p. 4040 - 4041
[5] Organic and Biomolecular Chemistry, 2012, vol. 10, # 12, p. 2439 - 2446
[6] Journal of Organic Chemistry, 2013, vol. 78, # 8, p. 3541 - 3552
[7] Patent: WO2014/140073, 2014, A1,
[8] Patent: US2015/191473, 2015, A1,
[9] Patent: CN104628771, 2016, B,
[10] Patent: US2017/291901, 2017, A1,
[11] European Journal of Inorganic Chemistry, 2018, vol. 2018, # 3, p. 517 - 524
[12] Chemistry - A European Journal, 2018, vol. 24, # 33, p. 8325 - 8330
[13] New Journal of Chemistry, 2018, vol. 42, # 20, p. 17062 - 17072
[14] Patent: WO2007/135417, 2007, A1,
  • 26
  • [ 870-46-2 ]
  • [ 100-52-7 ]
  • [ 24469-50-9 ]
YieldReaction ConditionsOperation in experiment
95% With pyridinium p-toluenesulfonate In dichloromethane at 20℃; for 0.123333 h; Flow reactor General procedure: General procedure for the continuous-flow hydrazone synthesis (products 3a-j) Following initiation of the control script, using the apparatus shown in Figure 3, the system was primed with dichloromethane and the aqueous extraction solvent for several minutes until there were no air gaps in the flow path. The aldehyde (0.20 M) and pyridinium paratoluenesulfonate (PPTS) (0.10 M) in dichloromethane (7.5 mL) were loaded in to the corresponding 7.5 mL injection loop. tert-Butyl carbazate (0.4 M) in dichloromethane (10.0 mL) was loaded into the 10.0 mL injection loop. The tert-butyl carbazate loop was injected into the system 30 seconds prior to the substrate loop. Organic solution exiting the system was collected for 40 minutes. The solvent was then removed under reduced pressure to afford a solid.
Reference: [1] ACS Medicinal Chemistry Letters, 2014, vol. 5, # 5, p. 462 - 467
[2] Chemistry - A European Journal, 2018, vol. 24, # 33, p. 8325 - 8330
[3] Journal of Heterocyclic Chemistry, 1986, vol. 23, p. 945 - 949
[4] Journal of Organic Chemistry, 1981, vol. 46, # 26, p. 5413 - 5414
[5] Journal of the American Chemical Society, [6] Journal of the American Chemical Society, 2008, vol. 130, p. 12907 - 12911
[7] Tetrahedron Letters, 2016, vol. 57, # 47, p. 5188 - 5191
[8] Canadian Journal of Chemistry, 2012, vol. 90, # 11, p. 985 - 993
[9] Journal of the American Chemical Society, 2004, vol. 126, # 21, p. 6759 - 6764
[10] Organic and Biomolecular Chemistry, 2016, vol. 14, # 5, p. 1579 - 1583
[11] Polish Journal of Chemistry, 2002, vol. 76, # 12, p. 1693 - 1697
[12] Journal of the Chemical Society. Perkin transactions 1, 1975, # 17, p. 1712 - 1720
[13] Journal of the American Chemical Society, 1960, vol. 82, p. 2728 - 2731
[14] Journal of the American Chemical Society, 1957, vol. 79, p. 98,100
[15] Journal of the Chemical Society, Chemical Communications, 1993, # 13, p. 1052 - 1053
[16] Bioorganic and Medicinal Chemistry Letters, 1997, vol. 7, # 3, p. 315 - 320
[17] Bioorganic and Medicinal Chemistry Letters, 2001, vol. 11, # 22, p. 2955 - 2958
[18] Patent: EP1184370, 2002, A2, . Location in patent: Example 19
[19] ACS Combinatorial Science, 2012, vol. 14, # 5, p. 323 - 334
[20] Tetrahedron Letters, 2013, vol. 54, # 8, p. 896 - 899
[21] Journal of Organic Chemistry, 2013, vol. 78, # 8, p. 3541 - 3552
[22] Organic Process Research and Development, 2007, vol. 11, # 3, p. 431 - 440
[23] Angewandte Chemie - International Edition, 2013, vol. 52, # 48, p. 12705 - 12708[24] Angew. Chem., 2013, vol. 125, # 48, p. 12937 - 12940,4
[25] Molecules, 2015, vol. 20, # 5, p. 9229 - 9241
[26] Organic and Biomolecular Chemistry, 2017, vol. 15, # 40, p. 8648 - 8654
[27] New Journal of Chemistry, 2018, vol. 42, # 20, p. 17062 - 17072
  • 27
  • [ 870-46-2 ]
  • [ 24469-50-9 ]
Reference: [1] Journal of Organic Chemistry, 1975, vol. 40, p. 3450 - 3452
  • 28
  • [ 870-46-2 ]
  • [ 14719-37-0 ]
Reference: [1] Tetrahedron, 1998, vol. 54, # 49, p. 14679 - 14688
[2] Tetrahedron, 1998, vol. 54, # 49, p. 14679 - 14688
  • 29
  • [ 870-46-2 ]
  • [ 127799-54-6 ]
Reference: [1] Journal of the American Chemical Society, 2004, vol. 126, # 21, p. 6759 - 6764
  • 30
  • [ 870-46-2 ]
  • [ 501-53-1 ]
  • [ 57699-88-4 ]
YieldReaction ConditionsOperation in experiment
98%
Stage #1: at 0 - 20℃;
Stage #2: With sodium hydrogencarbonate In dichloromethane; water
To a solution of fe/t-butyl carbazate (75 g, 567 mmol) in methylene chloride (2.0 L) at 0°C was added benzyl chloroformate over -45 minutes. After the addition was complete the reaction was stirred overnight coming to rt as the ice bath was depleted. The reaction was carefully poured into saturated sodium bicarbonate (1L) and extracted. The organic layer was washed with water, and dried over sodium sulfate. Removal of the solvent in vacuo gave the desired product (148 g, 556 mmol, 98percent crude yield) as a viscous oil. The material was judged to be of satisfactory purity without further purification.
85% With sodium carbonate In dichloromethane at -78 - 20℃; tert-Butyl hydrazinecarboxylate 10 (132 mg, 1 mmol) was dissolved in dry DCM and cooled down to -78 °C. Benzyl chloroformate (20.5 mg 1.2 mmol) was added drop-wise followed by Na2CO3 (106 mg, 1 mmol). The reaction mixture was allowed to rt and stirred overnight. Filtration, evaporation of solvents, and recrystallization from hexanes/EtOAc 50:1 gave 1-benzyl 2-(tert-butyl)hydrazine-1,2-dicarboxylate 11 as a white solid (226 mg, 85percent), mp 75.0–77.0 °C, lit. 72–74 °C. 1H NMR (300 MHz, CDCl3) δ 7.34 (s, 5H), 6.80 (s, 1H), 6.49 (s, 1H), 5.16 (s, 2H), 1.46 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 156.9, 155.9, 135.8, 128.7, 128.5, 128.4, 81.9, 67.8, 28.3.22
13.8 g With 4-methyl-morpholine In tetrahydrofuran at 0℃; To a cold solution (0° C) of tert-butyl hydrazinecarboxylate hydrochloride (7.1 g, 53.8 mmol) in and N-methylmorpholine (17.7 mL, 161 mmol) in tetrahydrofuran (100 mL) added benzyl chloroformate (7.7 g, 53.8 mmol) and slowly brings to room temperature stirred for 10 h. Tetrahydrofuran was removed under reduced pressure and the resulting viscous solution was diluted with water (40 mL) and thoroughly extracted with ethyl acetate (50x3 mL). The combined organic extracts were washed with 1 N HCl (25 mL), saturated aqueous sodium bicarbonate (NaHCO3) (25 mL) and dried over anhydrous sodium sulphate (Na2SO4) and concentrated to give a residue, which was purified by by silica gel column chromatography (EtOAc : Hexane – 2:5) as a white solid (13.8 g, yield: 96percent). 1H NMR (400 MHz, CDCl3) d ppm: 7.44 - 7.27 (m, 5 H), 6.48 (bs, 1 H), 6.29 (bs, 1 H), 5.18 (s, 1H), 1.46 (bs, 9 H). MS (ESI): found: [M + Na]+, 289.2.
Reference: [1] Patent: WO2008/65500, 2008, A2, . Location in patent: Page/Page column 67
[2] Tetrahedron, 2010, vol. 66, # 49, p. 9538 - 9544
[3] Tetrahedron Letters, 1992, vol. 33, # 36, p. 5209 - 5212
[4] Tetrahedron Letters, 2007, vol. 48, # 33, p. 5767 - 5770
[5] Journal of the American Chemical Society, 2004, vol. 126, # 21, p. 6759 - 6764
[6] Journal of the American Chemical Society, 2003, vol. 125, # 5, p. 1221 - 1235
[7] Tetrahedron Letters, 2015, vol. 56, # 48, p. 6653 - 6655
[8] Heterocycles, 2009, vol. 78, # 11, p. 2755 - 2768
[9] Patent: WO2017/189920, 2017, A1, . Location in patent: Sheet 4/7
[10] Tetrahedron, 1977, vol. 33, p. 739 - 743
[11] Journal of the Chemical Society. Perkin transactions 1, 1975, # 17, p. 1712 - 1720
[12] Tetrahedron Letters, 2001, vol. 42, # 30, p. 5009 - 5012
[13] Patent: US2010/204214, 2010, A1, . Location in patent: Page/Page column 115
[14] Patent: US2011/65694, 2011, A1, . Location in patent: Page/Page column 73
[15] Patent: WO2015/58163, 2015, A2, . Location in patent: Paragraph 410
[16] European Journal of Medicinal Chemistry, 2018, vol. 149, p. 193 - 210
  • 31
  • [ 870-46-2 ]
  • [ 21075-83-2 ]
Reference: [1] Journal of Organic Chemistry, 2000, vol. 65, # 14, p. 4370 - 4374
[2] ChemMedChem, 2018, vol. 13, # 16, p. 1681 - 1694
  • 32
  • [ 870-46-2 ]
  • [ 68014-21-1 ]
Reference: [1] Synthesis, 2002, # 1, p. 63 - 66
[2] Patent: US2013/253204, 2013, A1,
[3] Patent: US9212348, 2015, B2,
[4] Organic and Biomolecular Chemistry, 2017, vol. 15, # 43, p. 9071 - 9076
  • 33
  • [ 870-46-2 ]
  • [ 603-35-0 ]
  • [ 68014-21-1 ]
Reference: [1] Journal of Organic Chemistry, 2017, vol. 82, # 3, p. 1833 - 1841
  • 34
  • [ 870-46-2 ]
  • [ 35793-73-8 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2000, vol. 10, # 12, p. 1361 - 1363
  • 35
  • [ 870-46-2 ]
  • [ 21075-86-5 ]
Reference: [1] Journal of Organic Chemistry, 2000, vol. 65, # 14, p. 4370 - 4374
[2] ACS Chemical Biology, 2016, vol. 11, # 4, p. 921 - 930
[3] ChemMedChem, 2018, vol. 13, # 16, p. 1681 - 1694
[4] Patent: WO2017/75629, 2017, A2,
  • 36
  • [ 870-46-2 ]
  • [ 75844-69-8 ]
Reference: [1] Journal of the Chemical Society - Perkin Transactions 1, 1996, # 2, p. 219 - 224
  • 37
  • [ 870-46-2 ]
  • [ 86953-79-9 ]
Reference: [1] Journal of the Chemical Society - Perkin Transactions 1, 1996, # 2, p. 219 - 224
  • 38
  • [ 870-46-2 ]
  • [ 102831-44-7 ]
Reference: [1] Journal of Organic Chemistry, 2017, vol. 82, # 3, p. 1833 - 1841
  • 39
  • [ 870-46-2 ]
  • [ 53788-49-1 ]
Reference: [1] Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1987, vol. 26, p. 657 - 661
  • 40
  • [ 102-52-3 ]
  • [ 870-46-2 ]
  • [ 219580-32-2 ]
Reference: [1] Tetrahedron, 1998, vol. 54, # 49, p. 14679 - 14688
  • 41
  • [ 29943-42-8 ]
  • [ 870-46-2 ]
  • [ 693287-79-5 ]
YieldReaction ConditionsOperation in experiment
92% With sodium cyanoborohydride; acetic acid In methanol at 25℃; for 16 h; Step I:
To a solution of dihydro-2H-pyran-4(3H)-one (5 g, 0.05 mol) in MeOH (60 mL) was added tert-butyl tert-butyl hydrazinecarboxylate (7.92 g, 0.06 mol), AcOH (500 uL) and NaBH3CN (6.3 g, 0.1 mol).
The mixture was stirred at 25 °C for 16 hours, then concentrated.
The residue was dissolved in DCM (100 mL), washed with water (80 mL), dried over anhydrous Na2SO4, concentrated.
The crude residue was purified by silical gel chromatography (PE : EA = 5:1 to 1:1) to give tert-butyl tert-butyl 2-(tetrahydro-2H-pyran-4-yl)hydrazinecarboxylate (10 g, 92percent) as a white solid.
88%
Stage #1: at 20℃; for 3 h;
Stage #2: at 20℃; for 60 h;
Intermediate 221,1-Dimethylethyl 2-(tetrah dro-2H-pyran-4-yl)hydrazinecarboxylateTetrahydro-4H-pyran-4-one (9.69 g, 97 mmol) was added to a solution of 1,1- dimethylethyl hydrazinecarboxylate (14.07 g, 106 mmol) in methanol (100 mL) and stirred at room temperature for 3 h. The solvent was removed in vacuo, and the crude residue was suspended in acetic acid (140 mL). Next added sodium cyanoborohydride (6.69 g, 106 mmol) in portions over 3 minutes. The contents were stirred at room temperature for 60 h. The solvent was removed in vacuo, and the crude residue was suspended in DCM (100 mL). The reaction mixture was adjusted to pH 7 with 6N NaOH. The layers were separated, and the aq. layer extracted with DCM. The combined organic layers were washed with saturated NaHC03, and brine. The organic layer was dried over MgS04, filtered, and concentrated in vacuo to afford the product as a solid, 18.4 g (88percent). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.22 (m, 2 H), 1.39 (s, 9 H), 1.43 - 1.48 (m, 1 H), 1.59 - 1.69 (m, 2 H), 2.82 - 2.98 (m, 1 H), 3.20 - 3.32 (m, 2 H), 3.80 (d, J=l 1.62 Hz, 2 H), 4.36 (br. s., 1 H), 8.07 - 8.34 (m, 1 H).
88%
Stage #1: at 20℃; for 2 h;
Stage #2: at 20℃;
10 g (100 mmol) of tetrahydropyran-4-one was dissolved in 100 ml_ methanol and 14.5 g (110 mmol) tert-butylcarbazate was added. The reaction mixture was stirred at room temperature for 2h. The solvent was evaporated by reduced pressure. The residue was mixed with 140 ml_ acetic acid (50 percent), 6.9 g (110 mmol) sodium cyanoborohydride was added and the mixture was stirred at room temperature over night. The reaction mixture was neutralized with 4M NaOH and extracted with dichloromethane. The organic layer was washed with a saturated aqueous solution of sodium hydrogen carbonate and a saturated aqueous solution of sodium chloride. <n="175"/>The organic layer was dried over sodium sulphate, filtered, and the filtrate was concentrated under reduced pressure. 19 g (88 percent) of the product were obtained as a white solid.MS ( ESI pos ): m/z = 217 (IvRH)+
64%
Stage #1: With sodium cyanoborohydride; acetic acid In ethanol; water at 20℃; for 2.5 h;
Stage #2: With potassium carbonate In ethanol; water; ethyl acetate
A mixture of tetrahydro-4H-pyran-4-one (31.7mL, 0.34mol) and tert-butylcarbazate (47.7g, 0.36mol) in EtOH (50OmL) was stirred at ambient temperature overnight. The reaction mixture was evapotrated and the reisdue suspended in HOAc-H2O (1:1 / 50OmL). NaCNBH3 (22.64g,0.36mol) was added and the mixture was stirred at ambient temperature for 2.5hr. The reaction mixture was suspended in EtOAc-10percent K2CO3 (2:1 / 75OmL). The organic layer was separated, washed with brine (2 x 40OmL) and dried (MgSO4). Filtration and evaporation of the solvent and trituration of the residue with hexane afforded the product as a white amorphous solid(47.5g, 64percent). 1H NMR (CDCl3) 6.10 (IH, br s), 3.99-3.35 (5H, m), 3.06 (IH, m), 1.79-1.35(4H, m), 1.46 (9H, s)
2.34 g
Stage #1: at 10 - 35℃; for 1 h;
Stage #2: With sodium tetrahydroborate; acetic acid In tetrahydrofuran at 0℃; for 1 h;
A) tert-butyl 2-(tetrahydro-2H-pyran-4-yl)hydrazinecarboxylate [0431] A solution of tetrahydro-4H-pyran-4-one (2.50 g) and tert-butyl hydrazinecarboxylate (3.47 g) in methanol (10 mL) was stirred at room temperature for 1 hr, and concentrated under reduced pressure. The residue was dissolved in THF (25 mL), acetic acid (4.3 mL) and sodium borohydride (0.525 g) were added thereto, and the mixture was stirred at 0°C for 1 hr. To the reaction mixture was added 8N aqueous sodium hydroxide solution, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with saturated aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/hexane) to give the title compound (2.34 g). 1H NMR (300 MHz, CDCl3) δ 1.35-1.54 (11H, m), 1.77 (2H, dd, J = 12.1 Hz, 2.3 Hz), 2.98-3.15 (1H, m), 3.40 (2H, td, J = 11.3 Hz, 2.3 Hz), 3.96 (3H, dt, J = 11.5 Hz, 3.7 Hz), 6.03 (1H, brs).

Reference: [1] Patent: EP3147283, 2017, A1, . Location in patent: Paragraph 0110
[2] Journal of Medicinal Chemistry, 2007, vol. 50, # 20, p. 4789 - 4792
[3] Patent: WO2013/39988, 2013, A1, . Location in patent: Page/Page column 134
[4] Patent: WO2009/121919, 2009, A1, . Location in patent: Page/Page column 172-173
[5] Patent: WO2007/135350, 2007, A1, . Location in patent: Page/Page column 62
[6] Patent: EP1918284, 2008, A1, . Location in patent: Page/Page column 27-28
[7] Patent: WO2010/142628, 2010, A1, . Location in patent: Page/Page column 80-81
[8] Patent: EP2857400, 2015, A1, . Location in patent: Paragraph 0431
[9] Patent: US2015/191473, 2015, A1,
  • 42
  • [ 29943-42-8 ]
  • [ 870-46-2 ]
  • [ 64-19-7 ]
  • [ 1082745-70-7 ]
  • [ 693287-79-5 ]
YieldReaction ConditionsOperation in experiment
98%
Stage #1: at 20℃; for 20 h;
Stage #2: for 0.5 h;
To a solution of tetrahydropyran-4-one (71.6 g, 715 mmol) in methanol (2 L) was added tert-butylcarbazate (100 g, 758 mmol) at ambient temp.
The mixture was stirred at ambient temp for 20 h.
The reaction mixture was concentrated under reduced pressure to dryness to afford a white solid (154 g).
To a suspension of the white solid (154 g, 715 mmol) in water (1 L) was added acetic acid (500 mL, 8.73 mol) and the mixture was stirred for 30 min to get a clear solution.
To this solution, solid NaCNBH3 (44.5 g, 708 mmol) was added portion-wise.
The mixture was stirred at ambient temp for 2 h.
The mixture was then transferred to a 12 L flask, cooled to 0° C., and quenched with 1N NaOH (8.73 L, 8.73 mol).
The mixture was extracted with CH2Cl2 (3*3 L) and dried over Na2SO4.
The organic layer was filtered and concentrated to afford a white solid (164 g, contains ~15percent of N-acetyl-N'-Boc-hydrazine derivative).
Chromatography [silica, ethyl acetate/MeOH (95:5] gave 94 g of 90percent pure boc-hydrazine.
A solution of boc-hydrazine (50 g, 231 mmol) in methanol (500 mL) was added a solution of HCl in dioxane (462 mL, 1.85 mol, 4.0 M).
The mixture was stirred at ambient temp overnight.
Concentration of the reaction mixture under reduced pressure afforded the title compound as a white solid (43 g, 98percent).
400 MHz 1H NMR (DMSO) δ 3.85-3.82 (m, 2H), 3.27-3.21 (m, 2H), 3.13-3.05 (m, 1H), 1.88-1.84 (m, 2H), 1.48-1.38 (m, 2H). MS: (M+H m/z=117.2).
Reference: [1] Patent: US2009/30003, 2009, A1, . Location in patent: Page/Page column 35-36
  • 43
  • [ 870-46-2 ]
  • [ 693287-79-5 ]
Reference: [1] Journal of Medicinal Chemistry, 2004, vol. 47, # 9, p. 2180 - 2193
[2] Patent: WO2011/41399, 2011, A2,
[3] Patent: WO2013/177668, 2013, A1,
[4] Patent: WO2016/123392, 2016, A2,
  • 44
  • [ 29943-42-8 ]
  • [ 870-46-2 ]
  • [ 64-19-7 ]
  • [ 90271-04-8 ]
  • [ 693287-79-5 ]
Reference: [1] Journal of Medicinal Chemistry, 2012, vol. 55, # 21, p. 9045 - 9054
  • 45
  • [ 127406-56-8 ]
  • [ 870-46-2 ]
  • [ 198904-84-6 ]
YieldReaction ConditionsOperation in experiment
91.1% for 4 h; Heating / reflux Synthesis of tert-butyl 2-(4-(pyridin-2-yl)benzylidene)hydrazinecarboxylate (XII, Y1a = H).; A mixture of 4-(pyridin-2-yl)benzaldehyde X (17.7 g, 96.6 mmol) and tert-butyl carbazate (12.2 g, 92.3 mmol) in ethanol (125 mL) was kept at reflux under nitrogen for 4 hours (hrs). The reaction mixture was cooled to 40°C and ice (60 g) was added, The resulting mixture was stirred for 20 minutes (min). The precipitate was collected by filtration, washed with water and dried in a vacuum oven (60 °C) to give the product XII, wherein Y1a = H (25.0 g, 91.1 percent).
Reference: [1] Patent: EP2003120, 2008, A1, . Location in patent: Page/Page column 33
[2] Organic and Biomolecular Chemistry, 2013, vol. 11, # 39, p. 6806 - 6813
[3] Organic Process Research and Development, 2002, vol. 6, # 3, p. 323 - 328
[4] Patent: US6765097, 2004, B1, . Location in patent: Page column 14-15
[5] Patent: WO2010/149356, 2010, A1, . Location in patent: Page/Page column 14; 15
[6] Molecules, 2015, vol. 20, # 5, p. 9229 - 9241
[7] Patent: CN106543073, 2017, A, . Location in patent: Paragraph 0040; 0041
  • 46
  • [ 870-46-2 ]
  • [ 2991-28-8 ]
  • [ 1079843-62-1 ]
Reference: [1] Tetrahedron Letters, 2010, vol. 51, # 48, p. 6236 - 6239
[2] Patent: WO2006/31348, 2006, A2, . Location in patent: Page/Page column 28
[3] Patent: WO2006/44825, 2006, A2, . Location in patent: Page/Page column 55
  • 47
  • [ 870-46-2 ]
  • [ 35730-09-7 ]
  • [ 1079843-62-1 ]
Reference: [1] Patent: WO2009/52288, 2009, A1, . Location in patent: Page/Page column 319
[2] Patent: WO2009/61595, 2009, A1, . Location in patent: Page/Page column 300-301
[3] Patent: WO2010/132520, 2010, A1, . Location in patent: Page/Page column 315-316
  • 48
  • [ 870-46-2 ]
  • [ 937046-96-3 ]
Reference: [1] Patent: WO2011/150356, 2011, A1,
[2] ChemMedChem, 2018, vol. 13, # 5, p. 437 - 445
[3] Patent: WO2013/33093, 2013, A1,
  • 49
  • [ 870-46-2 ]
  • [ 4387-36-4 ]
  • [ 1204298-58-7 ]
Reference: [1] Journal of Organic Chemistry, 2013, vol. 78, # 7, p. 3400 - 3404
[2] Bioorganic and Medicinal Chemistry Letters, 2018,
  • 50
  • [ 870-46-2 ]
  • [ 2042-37-7 ]
  • [ 1204298-58-7 ]
Reference: [1] Journal of Organic Chemistry, 2013, vol. 78, # 7, p. 3400 - 3404
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 870-46-2 ]

Aliphatic Chain Hydrocarbons

Chemical Structure| 127799-54-6

[ 127799-54-6 ]

tert-Butyl 2-methylhydrazinecarboxylate

Similarity: 0.91

Chemical Structure| 19740-72-8

[ 19740-72-8 ]

Diisopropyl hydrazine-1,2-dicarboxylate

Similarity: 0.84

Chemical Structure| 4248-19-5

[ 4248-19-5 ]

tert-Butyl carbamate

Similarity: 0.83

Chemical Structure| 4114-31-2

[ 4114-31-2 ]

Ethyl hydrazinecarboxylate

Similarity: 0.83

Chemical Structure| 21075-83-2

[ 21075-83-2 ]

1-Boc-1-methylhydrazine

Similarity: 0.78

Amides

Chemical Structure| 127799-54-6

[ 127799-54-6 ]

tert-Butyl 2-methylhydrazinecarboxylate

Similarity: 0.91

Chemical Structure| 19740-72-8

[ 19740-72-8 ]

Diisopropyl hydrazine-1,2-dicarboxylate

Similarity: 0.84

Chemical Structure| 4248-19-5

[ 4248-19-5 ]

tert-Butyl carbamate

Similarity: 0.83

Chemical Structure| 4114-31-2

[ 4114-31-2 ]

Ethyl hydrazinecarboxylate

Similarity: 0.83

Chemical Structure| 21075-83-2

[ 21075-83-2 ]

1-Boc-1-methylhydrazine

Similarity: 0.78

Hydrazides

Chemical Structure| 127799-54-6

[ 127799-54-6 ]

tert-Butyl 2-methylhydrazinecarboxylate

Similarity: 0.91

Chemical Structure| 19740-72-8

[ 19740-72-8 ]

Diisopropyl hydrazine-1,2-dicarboxylate

Similarity: 0.84

Chemical Structure| 4114-31-2

[ 4114-31-2 ]

Ethyl hydrazinecarboxylate

Similarity: 0.83

Chemical Structure| 16689-35-3

[ 16689-35-3 ]

tert-Butyl 2-isopropylhydrazinecarboxylate

Similarity: 0.78

Chemical Structure| 21075-83-2

[ 21075-83-2 ]

1-Boc-1-methylhydrazine

Similarity: 0.78

Amines

Chemical Structure| 127799-54-6

[ 127799-54-6 ]

tert-Butyl 2-methylhydrazinecarboxylate

Similarity: 0.91

Chemical Structure| 19740-72-8

[ 19740-72-8 ]

Diisopropyl hydrazine-1,2-dicarboxylate

Similarity: 0.84

Chemical Structure| 4248-19-5

[ 4248-19-5 ]

tert-Butyl carbamate

Similarity: 0.83

Chemical Structure| 4114-31-2

[ 4114-31-2 ]

Ethyl hydrazinecarboxylate

Similarity: 0.83

Chemical Structure| 21075-83-2

[ 21075-83-2 ]

1-Boc-1-methylhydrazine

Similarity: 0.78

Hydrazines

Chemical Structure| 127799-54-6

[ 127799-54-6 ]

tert-Butyl 2-methylhydrazinecarboxylate

Similarity: 0.91

Chemical Structure| 19740-72-8

[ 19740-72-8 ]

Diisopropyl hydrazine-1,2-dicarboxylate

Similarity: 0.84

Chemical Structure| 4114-31-2

[ 4114-31-2 ]

Ethyl hydrazinecarboxylate

Similarity: 0.83

Chemical Structure| 16689-35-3

[ 16689-35-3 ]

tert-Butyl 2-isopropylhydrazinecarboxylate

Similarity: 0.78

Chemical Structure| 21075-83-2

[ 21075-83-2 ]

1-Boc-1-methylhydrazine

Similarity: 0.78